A randomized split-face clinical trial of conventional vs indoor-daylight photodynamic therapy for the treatment of multiple actinic keratosis of the face and scalp and photoaging

J Dermatolog Treat. 2022 Jun;33(4):2250-2256. doi: 10.1080/09546634.2021.1944594. Epub 2021 Jun 28.

Abstract

Background: Recently, indoor daylight photodynamic therapy (idl-PDT) has been developed; however, its efficacy and tolerability remain to be assessed.

Objective: This is a not-inferiority study to compare treatment outcomes of cPDT with a red LED lamp and idlPDT with a polychromatic white LED lamp in adult patients affected by symmetrical AKs of face and/or scalp.

Methods: In this comparative, intra-patient, split-face, randomized clinical trial forty-three adult patients were enrolled. Two contralateral and symmetrical target areas of the face and/or scalp harboring at least 5 AKs were selected and randomized 1:1 to treatment with cPDT and idlPDT. The AKs number and cumulative area were assessed at baseline (T0). Efficacy and cosmetic outcome were assessed 3 months after treatment (T1).

Results: Total AKs number and area reduced significantly with both idlPDT (p < .0001) and cPDT (p < .0001) in comparison to baseline. cPDT was more painful (p < .0001) and induced a more severe inflammation (p < .0001). Twenty-nine patients (70.7%) gave their overall preference to idlPDT (p < .001).

Conclusion: idlPDT may represent an alternative treatment protocol to cPDT for in-office treatment of AKs patients with better tolerability and a not inferior efficacy.

Keywords: PDT; actinic keratosis; indoor-daylight; photoaging; photodynamic therapy; split-face.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aminolevulinic Acid / therapeutic use
  • Humans
  • Keratosis, Actinic* / drug therapy
  • Photochemotherapy* / methods
  • Photosensitizing Agents / therapeutic use
  • Scalp
  • Scalp Dermatoses* / drug therapy
  • Skin Aging*
  • Treatment Outcome

Substances

  • Photosensitizing Agents
  • Aminolevulinic Acid